• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Profit, sales up at Boston Scientific

Profit, sales up at Boston Scientific

July 21, 2009 By MassDevice staff

Medical device maker Boston Scientific Corp. rebounded from a first-quarter loss earlier this year to post a $158-million profit during the three months ended June 30.

The 10-cent-a-share gain, after adjustments, slightly trailed analyst expectations for the Natick, Mass.-based manufacturer of stents, pacemakers and other devices but was at the high end of the company’s guidance.

Revenues for the quarter were $2.07 billion, slightly ahead of analyst and company projections. The results likewise compare favorably with a $98 million profit on $2.02 million in revenues during the June 2008 quarter.

“New products accounted for more than 40 percent of our sales this quarter, and we continue to bring a wide range of innovations to market,” said new CEO Ray Elliott, who will discuss the quarterly results Tuesday morning at 8 a.m. EST in his first conference call at the helm of the company.

U.S. regulators approved two new stents during the quarter as well as expanding uses for the company’s “Spyscope” catheter-delivery system. Boston Scientific also got the go-ahead to market several other new devices in Europe.

“These approvals position us well for the remainder of the year and, perhaps more important, provide a springboard into 2010,” Elliott said.

Sales rose 5.3 percent in the company’s global cardiovascular business, its largest, to $405 million from $364 million a year ago. However, the strongest growth was seen in the company’s stent sales, climbing $44 million, or 10 percent, to $484 million.

U.S. stent sales were particularly strong, up 26.5 percent to $253 million, and helped offset a small decline in international sales. The company also said its drug-eluting stents — mesh-like devices coated with heart medications — now account for half of the procedures performed in the United States.

Looking ahead, Boston Scientific said it expects third-quarter net income to range between 8 cents to 13 cents per share. Analysts expect adjusted earnings around $225 million, or about 15 cents per share, on average.

Filed Under: Business/Financial News

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy